LUNG-ROLL: Treatment Patterns and Cost of Illness of Lung Cancer in Canada

NCT ID: NCT07143110

Last Updated: 2025-08-27

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Total Enrollment: 60000 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2025-08-20
• Study Completion Date: 2027-09-30

Brief Summary

LUNG-ROLL is a retrospective cohort study that will describe the contemporary treatment patterns, prevalence and incidence, patient demographic and clinical characteristics, clinical outcomes, and healthcare resource use/costs for patients with lung cancer in Canada (specifically, Alberta and Ontario) using administrative data.

Conditions

Lung Neoplasms

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: RETROSPECTIVE

Study Groups

Non-Small Cell Lung Cancer (NSCLC)

No interventions assigned to this group

Small Cell Lung Cancer (SCLC)

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Patients with lung cancer between January 1, 2018 and end of the Selection Period.
• Patient is 18 years of age or older on diagnosis date.
• Patient has at least 12 months of health insurance coverage prior to the diagnosis date.

Exclusion Criteria

• Diagnosed with any other cancer in the 5-year period prior to January 1, 2018.
• Diagnosed with any other cancer concurrently (i.e., on the same date) as lung cancer diagnosis.
• Invalid or incomplete records for key variables (e.g., missing year of diagnosis, missing cancer type).
• Non-Ontario or non-Alberta resident on diagnosis date.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 130 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AstraZeneca

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Central Contacts

AstraZeneca Clinical Study Information Center

Role: CONTACT

information.center@astrazeneca.com

1-877-240-9479

Other Identifiers

D133HR00044

Identifier Type: -

Identifier Source: org_study_id